Sign in

    Charlie Haywood

    Research Analyst at Bank of America

    Charlie Haywood is an analyst at Bank of America specializing in financial sector research, though specific public details on his title, covered companies, and quantified track record remain limited. There are no visible metrics related to investment performance, success rates, or analyst rankings on platforms such as TipRanks, nor are any specific companies under coverage identified. Previous experience, a detailed career timeline, and formal professional credentials such as FINRA registration or securities licenses are not confirmed in publicly accessible sources. Without confirmation from LinkedIn or research databases, additional information on achievements, recognition, or specific sector specialties held by Charlie Haywood is currently unavailable.

    Charlie Haywood's questions to Zealand Pharma A/S/ADR (ZLDPF) leadership

    Charlie Haywood's questions to Zealand Pharma A/S/ADR (ZLDPF) leadership • Q1 2025

    Question

    Charlie Haywood of Bank of America asked about the company's vision for patient 'stay time' on petrelintide monotherapy and its ambitions for future R&D in the cardiometabolic space beyond the current pipeline.

    Answer

    CEO Adam Steensberg stated a much higher ambition for treatment duration than the ~7 months seen with GLP-1s, driven by petrelintide's superior tolerability profile for long-term maintenance. Regarding the pipeline, he confirmed significant new investments are planned and pointed to the December Capital Markets Day for a full vision, highlighting the Kv1.3 program as an example of future opportunities.

    Ask Fintool Equity Research AI

    Charlie Haywood's questions to Zealand Pharma A/S/ADR (ZLDPF) leadership • Q3 2024

    Question

    Charlie Haywood asked for an update on petrelintide partnering discussions, including the nature of the talks and if co-commercialization remains the goal. He also requested a comparison of petrelintide to Novo Nordisk's cagrilintide, focusing on dosing potential.

    Answer

    CEO Adam Steensberg and Chief Medical Officer David Kendall replied. Mr. Steensberg expressed high satisfaction with partnership talks, confirming that a co-development and co-commercialization deal remains the ambition and has been met with positive feedback. Dr. Kendall detailed petrelintide's potential advantages over cagrilintide, including a formulation allowing for up to 4x higher dose exposure, no observed immunogenicity, and independence from GLP-1 tolerability issues that could limit a fixed-dose combination.

    Ask Fintool Equity Research AI

    Charlie Haywood's questions to Zealand Pharma A/S/ADR (ZLDPF) leadership • Q3 2024

    Question

    Charlie Haywood from Bank of America asked for an update on petrelintide partnering discussions, including any key debates and whether a co-commercialization agreement remains the goal. He also asked for a comparison of petrelintide to Novo Nordisk's cagrilintide, particularly regarding potential dosing levels.

    Answer

    President and CEO Adam Steensberg reported being 'extremely pleased' with partnership discussions, confirming that the goal remains a co-development and co-commercialization deal, which has not faced significant pushback. Chief Medical Officer David Kendall contrasted petrelintide with cagrilintide, suggesting petrelintide can be dosed significantly higher (up to 4x) due to a more favorable formulation, better tolerability, and lack of immunogenicity, which he believes could lead to superior efficacy.

    Ask Fintool Equity Research AI